<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00911586</url>
  </required_header>
  <id_info>
    <org_study_id>CLAR-09009</org_study_id>
    <nct_id>NCT00911586</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study to Determine Time to Steady-state</brief_title>
  <official_title>Pharmacokinetic Study to Determine Time to Steady-state of an Oral Testosterone Undecanoate Formulation in Hypogonadal Men.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clarus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clarus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to confirm how long (i.e., how many days) it takes to reach
      steady-state when testosterone undecanoate is administered twice daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum testosterone levels will be obtained in hypogonadal (serum testosterone &lt;300 ng/dL)
      males receiving testosterone undecanoate capsules administered twice daily. Serum samples
      will be obtained consecutively in the morning on several days during one month of open-label
      treatment to confirm the time at which steady-state is reached.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmation of time to reach steady-state when oral testosterone undecanoate is administered twice daily.</measure>
    <time_frame>One month</time_frame>
  </primary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Male Hypogonadism</condition>
  <condition>Primary Hypogonadism</condition>
  <condition>Secondary Hypogonadism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone undecanoate</intervention_name>
    <description>Oral testosterone undecanoate, twice daily for one month.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, age 18-75

          -  Morning serum testosterone (T) &lt;300 ng/dL on two occasions

          -  Naive to androgen-replacement therapy or willing to wash-out from current T therapy

        Exclusion Criteria:

          -  Significant intercurrent disease

          -  Abnormal prostate digital rectal exam, elevated PSA, AUA symptom score &gt;15 or history
             of prostate cancer.

          -  Serum transaminases &gt;2 times upper limit of normal

          -  Serum bilirubin &gt;2.0 mg/dL

          -  Hematocrit &lt;35% or &gt;50%

          -  BMI &gt;36

          -  Untreated, obstructive sleep apnea.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Flippo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alabama Clinical Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2009</study_first_submitted>
  <study_first_submitted_qc>May 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2009</study_first_posted>
  <disposition_first_submitted>August 17, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 17, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 19, 2010</disposition_first_posted>
  <last_update_submitted>August 17, 2010</last_update_submitted>
  <last_update_submitted_qc>August 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert E. Dudley, PhD, President and CEO</name_title>
    <organization>Clarus Therapeutics, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

